Výsledky vyhledávání - "Chooi Peng Lee"

Final overall survival (OS) analysis of atezolizumab (atezo) monotherapy vs chemotherapy (chemo) in untreated locally advanced or metastatic urothelial carcinoma (mUC) from the Phase 3 IMvigor130 study

Autor: Aristotelis Bamias, Ian D. Davis, Matt D. Galsky, Jose Angel Arranz Arija, Eiji Kikuchi, Enrique Grande, Xavier Garcia del Muro, Se Hoon Park, Ugo De Giorgi, Boris Alekseev, Marina Mencinger, Kouji Izumi, Javier Puente, Jian-Ri Li, Fabiola Bene-Tchaleu, Sanjeev Mariathasan, Chooi Peng Lee, Sandrine Bernhard, Maria De Santis

Publikováno v: Journal of Clinical Oncology. 41:LBA441-LBA441

LBA441 Background: Two interim OS analyses from IMvigor130 demonstrated non-statistically significant OS benefit with atezo monotherapy (Arm B) vs placebo + platinum (investigator [INV] choice of carboplatin or cisplatin [carbo or cis])/gemcitabine (

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1befcc5d5a8b689c84441065d247c72c
https://doi.org/10.1200/jco.2023.41.6_suppl.lba441

Zobrazit plný text záznamu

Atezolizumab (atezo) + platinum/gemcitabine (plt/gem) vs placebo + plt/gem for first-line (1L) treatment (tx) of locally advanced or metastatic urothelial carcinoma (mUC): Final OS from the randomized Phase 3 IMvigor130 study

Publikováno v: Journal of Clinical Oncology. 41:LBA440-LBA440

LBA440 Background: The IMvigor130 primary analysis demonstrated statistically significant PFS benefit with 1L atezo + plt/gem (Arm A) vs placebo + plt/gem (Arm C) in pts with mUC (Galsky Lancet 2020). Interim data showed improved OS with Arm A vs C b

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3ac9e89d52d912dde806d17ee4871582
https://doi.org/10.1200/jco.2023.41.6_suppl.lba440

Zobrazit plný text záznamu

658MO Cisplatin (cis)-related immunomodulation and efficacy with atezolizumab (atezo) + cis- vs carboplatin (carbo)-based chemotherapy (chemo) in metastatic urothelial cancer (mUC)

Publikováno v: Annals of Oncology. 32:S682-S683

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::571a879af89d7acbc29a2881ea988ad9
https://doi.org/10.1016/j.annonc.2021.08.054

Zobrazit plný text záznamu

Abstract CT042: Atezolizumab (atezo) + platinum/gemcitabine (plt/gem) vs placebo + plt/gem in patients (pts) with previously untreated locally advanced or metastatic urothelial carcinoma (mUC): Updated overall survival (OS) from the randomized phase III study IMvigor130

Publikováno v: Cancer Research. 81:CT042-CT042

Background: The IMvigor130 primary analysis demonstrated a statistically significant progression-free survival (PFS) benefit and encouraging OS with atezo + plt/gem (Arm A) vs placebo + plt/gem (Arm C) as first-line mUC treatment, although interim OS

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c81ff0e0946bea5e0abd4e4bc72d8f8a
https://doi.org/10.1158/1538-7445.am2021-ct042

Zobrazit plný text záznamu

Atezolizumab (atezo) monotherapy versus chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma (mUC): Clinical outcomes by PD-L1 status in cisplatin (cis)-ineligible pts from the phase III IMvigor130 study

Publikováno v: Journal of Clinical Oncology. 39:434-434

434 Background: Atezo (anti–PD-L1) monotherapy is approved for cis-ineligible pts who have locally advanced or mUC with PD-L1–expressing immune cells on ≥ 5% of the tumor area (IC2/3 per VENTANA SP142 IHC assay). The IMvigor130 primary analysis

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::870485f4634e2c685f980f0833a9be29
https://doi.org/10.1200/jco.2021.39.6_suppl.434

Zobrazit plný text záznamu

Phase III LEAP-010 study: first-line pembrolizumab with or without lenvatinib in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)

Autor: Ramona F. Swaby, Barbara Burtness, Lisa Licitra, Makoto Tahara, Jean-Pascal Machiels, Ezra E.W. Cohen, Danny Rischin, Lillian L. Siu, Cecilia Pinheiro, Kevin J. Harrington, Ying Zhu, Chooi Peng Lee

Publikováno v: Journal of Clinical Oncology. 38:TPS6589-TPS6589

TPS6589 Background: The PD-1 inhibitor pembrolizumab is currently approved as first-line monotherapy for patients with R/M HNSCC whose tumors express PD-L1 combined positive score (CPS) ≥1. In a phase 1b/2 trial (NCT02501096) of pembrolizumab plus

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::66f0bdc94f2b9925e02a947c1d20c575
https://doi.org/10.1200/jco.2020.38.15_suppl.tps6589

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání